New reports to be issued following a Senate investigation and results from a clinical trial appear to further solidify the dangers associated with Avandia (rosiglitazone). As cited by The New York Times, the reports conclude that if Avandia patients switched to a similar diabetes drug, Actos, approximately 500 heart attacks and 300 cases of heart failure could be avoided every month.
These recent studies are just the latest in an extensive series of studies that have been critical of both the side-effects associated with Avandia and GlaxoSmithKline’s knowledge of the health risks when it aggressively marketed the drug.
The Senate investigation revealed:
- A 2003 study, sponsored by GlaxoSmithKline, diabetics who took Avandia had far more heart problems than those given placebos.
- In 2003, the World Health Organization sent GlaxoSmithKline an alert of the problems associated with Avandia
- In 2004, European regulators ordered Glaxo to conduct a study into Avandia’s safety following the reports of problems associated with Avandia
- In 2006 and 2007, broad-based studies of Avandia patients concluded that there were major safety concerns and the results were communicated to the FDA
As lawyers who frequently represent the elderly, we have many clients who have taken Avandia at some point in their lives– and at this point they are rightfully concerned. Avandia has been linked to two types of edema (swelling or accumulation of fluid). Peripheral edema is swelling of the extremities due to fluid buildup. Macular is the swelling and protein buildup in the eye area.
The edemas have been linked to congestive heart failure and heart attacks. Studies suggest that there is a 43% increase in having a heart attack in people who have taken Avandia than the general population.
In addition to heart problems, Avandia has been linked to the following adverse medical conditions:
- Blurred vision
- Decreased visual acuity
- Liver problems
- Weight gain
If you have concerns regarding your legal rights related to Avandia usage, we would be honored to speak with you. (888) 424-5757
Research Ties Diabetes Drug to Heart Woes, New York Times, February 20, 2010